Emergent Biosolutions EBS Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total revenues by Business | |||||
| Commercial Products | $226.1M-43.3% | $398.9M-19.8% | $497.3M+28.6% | $386.6M-11.7% | |
| MCM Products | $456.7M-10.4% | $509.8M+14.0% | $447.2M-22.8% | $579.6M-1.1% | |
| Segment adjusted gross margin reportable segments: by Business | |||||
| Commercial Products | $96.2M-54.8% | $213M-25.8% | $287M+26.8% | $226.3M-9.8% | |
| MCM Products | $298.3M-2.0% | $304.4M+101% | $151.3M-59.0% | $369.3M-6.1% | |
| Total depreciation by Business | |||||
| All other segment | $3.7M-63.0% | $10M-55.6% | $22.5M— | —— | |
| MCM Products | $18.1M-10.4% | $20.2M-11.4% | $22.8M-23.2% | $29.7M+20.2% | |
| Cost of goods and services sold by Business | |||||
| Commercial Products | $129.9M-30.1% | $185.9M-11.6% | $210.3M+31.2% | $160.3M-14.4% | |
| MCM Products | $158.4M-22.9% | $205.4M-30.6% | $295.9M+40.7% | $210.3M+7.6% | |
| Total revenues by Product | |||||
| All other revenue | $60.1M-55.4% | $134.9M+28.7% | $104.8M— | —— | |
| Commercial Product sales | $226.1M-43.3% | $398.9M-19.8% | $497.3M+28.6% | $386.6M-11.7% | |
| MCM Product sales | $456.7M-10.4% | $509.8M+14.0% | $447.2M-22.8% | $579.6M-1.1% | |
| Concentration risk percentage by Product | |||||
| Anthrax MCM | 17%+2.0pp | 15%-5.0pp | 20%-10.0pp | 30%+4.0pp | |
| Naloxone products | 33%-11.0pp | 44%-7.0pp | 51%— | —— | |
| Other Commercial Products | 0%— | 0%-1.0pp | 1%0.0pp | 1%— | |
| Other Products | 11%+1.0pp | 10%0.0pp | 10%+4.0pp | 6%0.0pp | |
| Smallpox MCM | 39%+8.0pp | 31%+13.0pp | 18%-6.0pp | 24%-2.0pp | |
| Total revenues by Geography | |||||
| Canada | $75M-46.6% | $140.4M-37.4% | $224.2M+50.9% | $148.6M+123% | |
| Other | $136.8M+69.7% | $80.6M-63.0% | $217.9M+163% | $82.8M-0.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Emergent Biosolutions break its business down?
- Emergent Biosolutions (EBS) reports total revenues by business across 2 parts — Commercial Products and MCM Products. Each is extracted from the segment footnotes and tracked over time.
- Where does Emergent Biosolutions's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Emergent Biosolutions's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
